- Home
- EVMN vs DHY Comparison
EVMN vs DHY Comparison
Compare EVMN & DHY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EVMN | DHY |
|---|---|---|
| Founded | 2020 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 241.3M | 240.4M |
| IPO Year | 2025 | 1998 |
Fundamental Metrics
Financial Performance| Metric | EVMN | DHY |
|---|---|---|
| Price | $5.89 | $16.23 |
| Analyst Decision | Buy | |
| Analyst Count | 12 | 0 |
| Target Price | ★ $22.33 | N/A |
| AVG Volume (30 Days) | ★ 816.5K | 724.8K |
| Earning Date | 11-07-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 75.23 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $13,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 85.71 | N/A |
| 52 Week Low | $6.02 | $1.61 |
| 52 Week High | $33.20 | $16.67 |
Technical Indicators
Market Signals| Indicator | EVMN | DHY |
|---|---|---|
| Relative Strength Index (RSI) | 17.99 | 97.12 |
| Support Level | N/A | $1.77 |
| Resistance Level | $13.35 | $16.67 |
| Average True Range (ATR) | 0.47 | 0.23 |
| MACD | -0.05 | 0.72 |
| Stochastic Oscillator | 1.31 | 97.01 |
Price Performance
Historical ComparisonAbout EVMN Evommune Inc.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.
About DHY Credit Suisse High Yield Bond Fund
Credit Suisse High Yield Credit Fund is a diversified, closed-end management investment company. The Fund's principal investment objective is to generate current income. Capital appreciation is a secondary objective, pursued to the extent consistent with the Fund's primary income objective.